AI assistant
Vaxcyte, Inc. — Director's Dealing 2025
Sep 4, 2025
31100_dirs_2025-09-04_f0d69b88-5f4e-4cfc-9fd7-f728771b6789.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-09-02
Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-02 | Common Stock | F | 1270 | $31.56 | Disposed | 149286 | Direct |
| 2025-09-02 | Common Stock | F | 1587 | $31.56 | Disposed | 147699 | Direct |
| 2025-09-02 | Common Stock | F | 1429 | $31.56 | Disposed | 146270 | Direct |
Footnotes
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities
Exchange Act of 1934, as amended. On April 1, 2025, the Reporting Person transferred 1,689 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings.
F3: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.